Back

Tricuspid regurgitation and atrial fibrillation at baseline independently predict two-year survival after transcatheter aortic valve implantation (TAVI)

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Challenges in transcatheter aortic valve intervention Intervention ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Professor Marcus Franz

Cardiovascular Center Rotenburg an der Fulda, Rotenburg an der Fulda (Germany)

4 More presentations in this session

Presentation thumbnail
Man-machine interaction-based phenotyping preprocedurally identifies patients with severe aortic stenosis, who will not recover from cardiac damage following transcatheter aortic valve replacement
Miss E. Rippen (Munich, DE)
Abstract Slides
Presentation thumbnail
Phenotyping patients with aortic stenosis using cluster analysis to determine mortality and suitability for transcatheter aortic valve replacement
Doctor J. Sen (Melbourne, AU)
Abstract Slides
Presentation thumbnail
Prognostic relevance of mitral regurgitation at different follow-up timepoints after transcatheter aortic valve implantation (TAVI): implications for therapeutic decision making?
Professor M. Franz (Rotenburg an der Fulda, DE)
Abstract Slides
Presentation thumbnail
Optimal protamine-to-heparin dosing ratio for the prevention of bleeding complications in patients undergoing TAVR - a multicentre experience
Doctor B. Al-Kassou (Bonn, DE)
Abstract Slides

Access the full session

Session thumbnail
Challenges in transcatheter aortic valve intervention

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources